Annals of Hepato-Biliary-Pancreatic Surgery

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2508-5859   pISSN 2508-5778

Table. 3.

Table. 3.

A comparison between patients with and without postoperative pancreatic fistula

Variable Clinical significant pancreatic fistula p-value

No (n = 259) Yes (n = 29)
Study period 0.195
Jan 2003 to Jun 2011 74 (93.7) 5 (6.3)
Jul 2011 to Dec 2019 185 (88.5) 24 (11.5)
Age (yr) 63.3 ± 10.4 65.8 ± 8.9 0.213
Sex 0.611
Male 148 (57.1) 18 (62.1)
Female 111 (42.9) 11 (37.9)
ASA 0.489
1 41 (15.8) 5 (17.2)
2 167 (64.5) 16 (55.2)
3 51 (19.7) 8 (27.6)
Hemoglobin (g/dL) 12.2 ± 1.6 12.7 ± 1.9 0.094
Platelet (× 109/L) 261.6 ± 89.8 264.8 ± 110.5 0.860
White cell count (× 109/L) 6.8 ± 2.4 7.8 ± 4.0 0.059
International normalized ratio 1.01 ± 0.08 0.98 ± 0.07 0.116
Creatinine (mmol/L) 75.0 ± 21.7 83.3 ± 25.0 0.054
Albumin (g/L) 36.5 ± 5.8 35.1 ± 6.8 0.237
Bilirubin (mmol/L) 58.8 ± 91.2 67.9 ± 114.0 0.621
Alkaline phosphatase (IU/L) 213.1 ± 207.3 161.4 ± 135.2 0.199
Pancreas texture < 0.001*
Soft 166 (64.1) 28 (96.6)
Hard 93 (35.9) 1 (3.4)
Carcinoma of pancreas 88 (34.0) 4 (13.8) 0.027*
Pancreatic duct size (mm) 4.1 ± 2.2 3.2 ± 2.2 0.031*
Pancreatic duct size (mm) (exclude duct measurement by CT or MRI) 4.2 ±2.3 (n = 230) 3.3 ± 2.3 (n = 26) 0.046*
Operative approach 0.577
Open 252 (97.3) 28 (96.6)
Laparoscopic/robotic to open 3 (1.2) 1 (3.4)
Robotic 4 (1.5) 0 (0.0)
Concomitant procedure 10 (3.9) 2 (6.9) 0.345
Use of pancreatic stent 35 (13.5) 4 (13.8) > 0.999
Prophylactic Sandostatin 246 (95.0) 28 (96.6) > 0.999
Operative time (min) 530.1 ± 84.1 541.9 ± 74.5 0.472
Blood loss (mL) 697.2 ± 822.1 1,125.3 ± 1,986.5 0.260
Vascular resection 13 (5.0) 1 (3.4) > 0.999
Blood transfusion 52 (20.1) 9 (31.0) 0.171

Values are presented as number (%) or mean ± standard deviation.

ASA: American Society of Anesthesiologists.

*Statistically significant (p<0.05).

Ann Hepatobiliary Pancreat Surg 2022;26:84-90 https://doi.org/10.14701/ahbps.21-054
© 2021 Ann Hepatobiliary Pancreat Surg